Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) has received court approval to acquire assets of Invitae (OTC:NVTAQ), a leading medical genetics company, for $239 million in cash and non-cash consideration. The acquisition will advance Labcorp's specialty testing strategy in areas like oncology and rare diseases. The transaction is expected to enhance patient care, provide insights into health, and support clinical trials and treatment regimens.
Geneoscopy, Inc. announces FDA approval for its noninvasive colorectal cancer screening test, ColoSense, with 93% sensitivity for detecting colorectal cancer and 45% sensitivity for detecting advanced adenomas in average-risk individuals. The breakthrough device provides a dynamic view of disease activity using RNA biomarkers, offering a promising tool for early-age onset CRC detection. The study showed 100% sensitivity for CRC in the 45-49 age group, a critical demographic, with a commercial launch planned in collaboration with Labcorp.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.